18
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

10-July-cd-ia-medi-546-1145-sap-v2 redaction FINAL · 0hg,ppxqh 6wdwlvwlfdo $qdo\vlv 3odq iru 3urwrfro &' ,$ 0(', $qliuroxpde 2fw )lqdo yhuvlrq &21),'(17,$/ $1' 35235,(7$5< ri 6$3

  • Upload
    others

  • View
    0

  • Download
    0

Embed Size (px)

Citation preview

Page 1: 10-July-cd-ia-medi-546-1145-sap-v2 redaction FINAL · 0hg,ppxqh 6wdwlvwlfdo $qdo\vlv 3odq iru 3urwrfro &' ,$ 0(', $qliuroxpde 2fw )lqdo yhuvlrq &21),'(17,$/ $1' 35235,(7$5< ri 6$3
Page 2: 10-July-cd-ia-medi-546-1145-sap-v2 redaction FINAL · 0hg,ppxqh 6wdwlvwlfdo $qdo\vlv 3odq iru 3urwrfro &' ,$ 0(', $qliuroxpde 2fw )lqdo yhuvlrq &21),'(17,$/ $1' 35235,(7$5< ri 6$3

Statistical Analysis Plan

Page 3: 10-July-cd-ia-medi-546-1145-sap-v2 redaction FINAL · 0hg,ppxqh 6wdwlvwlfdo $qdo\vlv 3odq iru 3urwrfro &' ,$ 0(', $qliuroxpde 2fw )lqdo yhuvlrq &21),'(17,$/ $1' 35235,(7$5< ri 6$3

TABLE OF CONTENTS

Page 4: 10-July-cd-ia-medi-546-1145-sap-v2 redaction FINAL · 0hg,ppxqh 6wdwlvwlfdo $qdo\vlv 3odq iru 3urwrfro &' ,$ 0(', $qliuroxpde 2fw )lqdo yhuvlrq &21),'(17,$/ $1' 35235,(7$5< ri 6$3
Page 5: 10-July-cd-ia-medi-546-1145-sap-v2 redaction FINAL · 0hg,ppxqh 6wdwlvwlfdo $qdo\vlv 3odq iru 3urwrfro &' ,$ 0(', $qliuroxpde 2fw )lqdo yhuvlrq &21),'(17,$/ $1' 35235,(7$5< ri 6$3

List of Abbreviations

Page 6: 10-July-cd-ia-medi-546-1145-sap-v2 redaction FINAL · 0hg,ppxqh 6wdwlvwlfdo $qdo\vlv 3odq iru 3urwrfro &' ,$ 0(', $qliuroxpde 2fw )lqdo yhuvlrq &21),'(17,$/ $1' 35235,(7$5< ri 6$3
Page 7: 10-July-cd-ia-medi-546-1145-sap-v2 redaction FINAL · 0hg,ppxqh 6wdwlvwlfdo $qdo\vlv 3odq iru 3urwrfro &' ,$ 0(', $qliuroxpde 2fw )lqdo yhuvlrq &21),'(17,$/ $1' 35235,(7$5< ri 6$3
Page 8: 10-July-cd-ia-medi-546-1145-sap-v2 redaction FINAL · 0hg,ppxqh 6wdwlvwlfdo $qdo\vlv 3odq iru 3urwrfro &' ,$ 0(', $qliuroxpde 2fw )lqdo yhuvlrq &21),'(17,$/ $1' 35235,(7$5< ri 6$3
Page 9: 10-July-cd-ia-medi-546-1145-sap-v2 redaction FINAL · 0hg,ppxqh 6wdwlvwlfdo $qdo\vlv 3odq iru 3urwrfro &' ,$ 0(', $qliuroxpde 2fw )lqdo yhuvlrq &21),'(17,$/ $1' 35235,(7$5< ri 6$3

whether the manifestation is “present” or "absent" in the last 4 weeks. It is a weighted instrument, in which descriptors are multiplied by a particular organ’s “weight”. Fo

2K 6

42K 6

whether the manifestation is “present” or "absent" in the last 4 weeks. It is a weightedinstrument, in which descriptors are multiplied by a particular organ’s “weight”. Fo

2K 6

42K 6

Page 10: 10-July-cd-ia-medi-546-1145-sap-v2 redaction FINAL · 0hg,ppxqh 6wdwlvwlfdo $qdo\vlv 3odq iru 3urwrfro &' ,$ 0(', $qliuroxpde 2fw )lqdo yhuvlrq &21),'(17,$/ $1' 35235,(7$5< ri 6$3
Page 11: 10-July-cd-ia-medi-546-1145-sap-v2 redaction FINAL · 0hg,ppxqh 6wdwlvwlfdo $qdo\vlv 3odq iru 3urwrfro &' ,$ 0(', $qliuroxpde 2fw )lqdo yhuvlrq &21),'(17,$/ $1' 35235,(7$5< ri 6$3

The gene signature and the neutralization levels will be . Subgroup analysis of

Page 12: 10-July-cd-ia-medi-546-1145-sap-v2 redaction FINAL · 0hg,ppxqh 6wdwlvwlfdo $qdo\vlv 3odq iru 3urwrfro &' ,$ 0(', $qliuroxpde 2fw )lqdo yhuvlrq &21),'(17,$/ $1' 35235,(7$5< ri 6$3

Page 13: 10-July-cd-ia-medi-546-1145-sap-v2 redaction FINAL · 0hg,ppxqh 6wdwlvwlfdo $qdo\vlv 3odq iru 3urwrfro &' ,$ 0(', $qliuroxpde 2fw )lqdo yhuvlrq &21),'(17,$/ $1' 35235,(7$5< ri 6$3

o

o– –

serious AEs are captured during the first year of subject’s participation only.

o

o

Page 14: 10-July-cd-ia-medi-546-1145-sap-v2 redaction FINAL · 0hg,ppxqh 6wdwlvwlfdo $qdo\vlv 3odq iru 3urwrfro &' ,$ 0(', $qliuroxpde 2fw )lqdo yhuvlrq &21),'(17,$/ $1' 35235,(7$5< ri 6$3
Page 15: 10-July-cd-ia-medi-546-1145-sap-v2 redaction FINAL · 0hg,ppxqh 6wdwlvwlfdo $qdo\vlv 3odq iru 3urwrfro &' ,$ 0(', $qliuroxpde 2fw )lqdo yhuvlrq &21),'(17,$/ $1' 35235,(7$5< ri 6$3

MedImmune’s Clinical Pharmacology & DMPK group.

Page 16: 10-July-cd-ia-medi-546-1145-sap-v2 redaction FINAL · 0hg,ppxqh 6wdwlvwlfdo $qdo\vlv 3odq iru 3urwrfro &' ,$ 0(', $qliuroxpde 2fw )lqdo yhuvlrq &21),'(17,$/ $1' 35235,(7$5< ri 6$3

6 20

7 and decrease from BL 1.5

0.18 0.64

0.21 and decrease from BL 15%

2, <1 20

20

0.5

0.5, 0.25 10.0

1.4, 5.0

1.5, 5.0

1.0, 2.0

20 600

50 and decrease from BL 25

4.5

3 x ULN, 5 x ULN

3 x ULN, 5 x ULN

3 x ULN

500, 2000

5 x ULN

2 x ULN

Page 17: 10-July-cd-ia-medi-546-1145-sap-v2 redaction FINAL · 0hg,ppxqh 6wdwlvwlfdo $qdo\vlv 3odq iru 3urwrfro &' ,$ 0(', $qliuroxpde 2fw )lqdo yhuvlrq &21),'(17,$/ $1' 35235,(7$5< ri 6$3

20 100

25 and decrease from BL 10 70 and increase from BL 10

18

140, 190

132 152

3 5.5

90 120

2.5 7.0, 11.1

7.25

0.395

0.8

5.2

3.6, 5.4

Page 18: 10-July-cd-ia-medi-546-1145-sap-v2 redaction FINAL · 0hg,ppxqh 6wdwlvwlfdo $qdo\vlv 3odq iru 3urwrfro &' ,$ 0(', $qliuroxpde 2fw )lqdo yhuvlrq &21),'(17,$/ $1' 35235,(7$5< ri 6$3

50 120

50 and decrease from BL 20 120 and increase from BL 20

90 160

90 and decrease from BL 20 160 and increase from BL 20

50 100

50 and decrease from BL 10 100 and increase from BL 10